Ronald G Nahass MD MHCM,FIDSA
HIV/AIDS Medicine, Healthcare Associated Infections, Mycobacterial Disease
President-ID CARE, Clinical Professor of Medicine, Rutgers-RW Johnson Medical School
Join to View Full Profile
105 Raider BlvdSuite 101Hillsborough, NJ 08844
Phone+1 908-281-0221
Fax+1 908-281-0890
Dr. Nahass is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ronald Nahass, MD, is an infectious disease specialist based in Hillsborough, NJ, with subspecialties in HIV/AIDS Medicine, Healthcare Associated Infections, and Mycobacterial Disease. He completed his medical education and residency at Rutgers Robert Wood Johnson Medical School and holds a Master's in Healthcare Leadership from Harvard School of Public Health. Dr. Nahass is currently the President of ID CARE at Infectious Disease Care. His areas of expertise include hepatitis B, hepatitis C, HIV/AIDS, and antivirals for hepatitis C and HIV. He has contributed to several publications on HIV treatment and infectious diseases and has been involved in multiple clinical trials focused on HCV and other infections. Dr. Nahass has been recognized as one of America's Top Doctors by Castle Connolly and received multiple certifications for CMS Meaningful Use.
Education & Training
Harvard School of Public HealthMHCM, Healthcare Leadership, 2010 - 2012
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1982 - 1986
Rutgers Robert Wood Johnson Medical SchoolClass of 1982- Rensselaer Polytechnic InstituteB.S., Cum Laude, 1979
Certifications & Licensure
FL State Medical License 2020 - Present
NJ State Medical License 1983 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2016, 2023-2025
- New York Magazine: Top Doctors Castle Connolly, 2010-2018
- Top Doctors: New York Metro Area Castle Connolly
Clinical Trials
- A Study of the Long-Term Outcomes of HIV-Positive Patients Start of enrollment: 1999 Mar 01
- Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs Start of enrollment: 1999 Sep 01
- An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Start of enrollment: 2000 Mar 01
Publications & Presentations
PubMed
- Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.Amy E Colson, Gordon E Crofoot, Peter J Ruane, Moti N Ramgopal, Alexandra W Dretler
Annals of Internal Medicine. 2026-02-01 - Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.Marshall Yuan, Andrew Wassef, Davit Sargsyan, Vahe Nersisyan, Javier Cabrera
Journal of Medical Virology. 2025-06-01 - GS143, an inhibitor of E3 ligase β-TrCP, reverses HIV-1 latency without activating T cells via unconventional activation of NFκB.Srijata Sarkar, Yoshifumi Kobayashi, Timothy Russnak, Jing Shen, Ronald G Nahass
Plos Pathogens. 2025-04-01
Journal Articles
- Linkage to Care for Hepatitis C Virus (HCV) Among Suburban Heroin Users in New JerseyAkyar E, Seneca KH, Akyar S, Schoefield N, Schwartz MP, Nahass RG, Emerg Infect Dis, 1/1/2016
- Thorn-Induced Alternaria septic arthritis and osteomyelitis of the handLi Boning, Boretz R, Nahass RG, Infect Dis Clin Practice, 1/1/2016
- PegInterferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes wit...Foster GR, Pianko C, Cooper,A Brown A,Forton D, Nahass RG, Sofosbuvir, Hepatology, 1/1/2015
Abstracts/Posters
- High efficacy of sofosbuvir/velpatasvir plus gs-9857 for 12 weeks in treatment-experienced genotype 1-6 hcv-infected patients, including those previously treated with ...Lawitz E, Kowdley K, Curry M, Reau N, Nguyen M, Kwo P, Jacobson I, Tran T, Nahass RG, EASL, Barcelona, Spain, 1/1/2016
- C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)Dore GJ, Altice F, Litwin AH, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, et al, EASL, Barcelona, Spain, 1/1/2016
- High efficacy of grazoprevir/elbasvir among HCV GT1, GT4, or GT6 infected patients with HIV Co InfectionNelson M, Rockstroh J, Mallolas J, Katlama C, Nahass RG, et al, ID Week, San Diego, CA, 1/1/2015
Authored Content
- Talking to Patients About Measles, Vitamin A and the Importance of VaccinationMarch 2025
Press Mentions
President’s Proposed $22M Increase for AMR Is Needed but Will Be Hampered by Other CutsApril 7th, 2026- Newly Introduced Legislation Provides Pathway to Spur Antimicrobial DevelopmentFebruary 4th, 2026
- IDSA Statement on Immigration Enforcement and Access to Health CareJanuary 27th, 2026
Professional Memberships
- Fellow
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
